Pages that link to "Q45305137"
Jump to navigation
Jump to search
The following pages link to Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study (Q45305137):
Displaying 50 items.
- Endothelin receptor antagonists for pulmonary arterial hypertension (Q24200714) (← links)
- Endothelin receptor antagonists for pulmonary arterial hypertension (Q24240009) (← links)
- Endothelin receptor antagonists for pulmonary arterial hypertension (Q24245506) (← links)
- Phosphodiesterase 5 inhibitors for pulmonary hypertension (Q24245844) (← links)
- New therapeutic strategies for systemic sclerosis--a critical analysis of the literature (Q24649115) (← links)
- Cold hands--strained heart? Advances in the management of Raynaud's phenomenon and pulmonary hypertension (Q24816970) (← links)
- Cardiomyocyte-specific overexpression of HEXIM1 prevents right ventricular hypertrophy in hypoxia-induced pulmonary hypertension in mice (Q28484674) (← links)
- Increased right ventricular Septomarginal trabeculation mass is a novel marker for pulmonary hypertension: comparison with ventricular mass index and right ventricular mass (Q30464126) (← links)
- Cardiovascular magnetic resonance in pulmonary hypertension (Q30469534) (← links)
- The adult patient with eisenmenger syndrome: a medical update after dana point part I: epidemiology, clinical aspects and diagnostic options (Q30473252) (← links)
- Living with pulmonary hypertension: unique insights from an international ethnographic study (Q30578342) (← links)
- Network meta-analysis combining individual patient and aggregate data from a mixture of study designs with an application to pulmonary arterial hypertension (Q30936117) (← links)
- Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy? (Q33532813) (← links)
- Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent (Q33573360) (← links)
- Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension (Q33594460) (← links)
- Targeted drugs for pulmonary arterial hypertension: a network meta-analysis of 32 randomized clinical trials (Q33673947) (← links)
- Identifying "super responders" in pulmonary arterial hypertension. (Q33788452) (← links)
- Recent achievements in the management of Raynaud's phenomenon (Q33797622) (← links)
- Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies (Q33849207) (← links)
- Simvastatin as a treatment for pulmonary hypertension trial. (Q33868613) (← links)
- Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension (Q33892575) (← links)
- Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary arterial hypertension associated with connective tissue diseases (Q33965825) (← links)
- Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Biomarkers in pulmonary arterial hypertension (Q33965859) (← links)
- Are hemodynamics surrogate end points in pulmonary arterial hypertension? (Q34098418) (← links)
- Changes in healthcare utilization and costs associated with sildenafil therapy for pulmonary arterial hypertension: a retrospective cohort study (Q34508862) (← links)
- Simvastatin, Sildenafil and Their Combination in Monocrotaline Induced Pulmonary Arterial Hypertension (Q34512580) (← links)
- Sildenafil improves alveolar growth and pulmonary hypertension in hyperoxia-induced lung injury (Q34558395) (← links)
- Novel computed tomographic chest metrics to detect pulmonary hypertension (Q34778427) (← links)
- Modulation of endothelin receptors in the failing right ventricle of the heart and vasculature of the lung in human pulmonary arterial hypertension (Q34889050) (← links)
- Geometry of the randomized evidence for treatments of pulmonary hypertension (Q35013676) (← links)
- Non-congenital heart disease associated pediatric pulmonary arterial hypertension (Q35165691) (← links)
- Diagnosis and Management of Pulmonary Arterial Hypertension (Q35222937) (← links)
- Overview of current therapeutic approaches for pulmonary hypertension. (Q35412362) (← links)
- Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases. (Q35500693) (← links)
- Right ventricular remodeling in idiopathic and scleroderma-associated pulmonary arterial hypertension: two distinct phenotypes (Q35665758) (← links)
- Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy (Q35792872) (← links)
- Quantitative estimation of right ventricular hypertrophy using ECG criteria in patients with pulmonary hypertension: A comparison with cardiac MRI. (Q35896201) (← links)
- Novel peptide for attenuation of hypoxia-induced pulmonary hypertension via modulation of nitric oxide release and phosphodiesterase -5 activity (Q35909288) (← links)
- Sildenafil in the treatment of pulmonary hypertension (Q36013070) (← links)
- Comparative Effectiveness of Pharmacologic Interventions for Pulmonary Arterial Hypertension: A Systematic Review and Network Meta-Analysis. (Q36129391) (← links)
- Current treatment strategies for pulmonary arterial hypertension (Q36237720) (← links)
- Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension (Q36272405) (← links)
- Right ventricular plasticity and functional imaging (Q36366076) (← links)
- Pulmonary arterial hypertension: new insights and new hope (Q36372605) (← links)
- Update in pulmonary hypertension 2005. (Q36403168) (← links)
- Acquired right ventricular dysfunction (Q36423671) (← links)
- Sildenafil citrate for the treatment of pulmonary arterial hypertension. (Q36429756) (← links)
- A New Era in Medical Management of Severe Pediatric Pulmonary Arterial Hypertension (Q36481525) (← links)
- Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension (Q36484894) (← links)
- Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure (Q36512551) (← links)